ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

KYMR Kymera Therapeutics Inc

31.27
0.07 (0.22%)
20 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Kymera Therapeutics Inc KYMR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.07 0.22% 31.27 15:05:46
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
30.95 30.20 32.08 31.27 31.20
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
20/6/202407:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202406:00GLOBEKymera Therapeutics Presents New Clinical Data from the..
01/6/202407:00GLOBEKymera Therapeutics Presents New Clinical Data from Ongoing..
29/5/202406:00GLOBEKymera Therapeutics to Participate in Upcoming June Investor..
23/5/202416:00GLOBEKymera Therapeutics to Present New Clinical Data from..
22/5/202410:20GLOBEKymera Therapeutics Presents New Preclinical Data for..
14/5/202409:00GLOBEKymera Therapeutics to Present New Clinical Data from the..
08/5/202406:00GLOBEKymera Therapeutics to Participate in Upcoming May Investor..
02/5/202406:00GLOBEKymera Therapeutics Announces First Quarter 2024 Financial..
25/4/202406:00GLOBEKymera Therapeutics to Report First Quarter 2024 Financial..
08/4/202406:00GLOBEKymera Therapeutics Announces Scientific Presentations at..
08/3/202409:00GLOBEKymera Therapeutics Presents Preclinical Data for STAT6 and..
04/3/202417:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202417:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202417:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202416:50EDGAR2Form 144 - Report of proposed sale of securities
04/3/202416:47EDGAR2Form 144 - Report of proposed sale of securities
28/2/202406:00GLOBEKymera Therapeutics to Participate in Upcoming March..
27/2/202415:22EDGAR2Form 144 - Report of proposed sale of securities
22/2/202406:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202406:10EDGAR2Form 8-K - Current report
22/2/202406:00GLOBEKymera Therapeutics Announces Fourth Quarter and Full Year..
15/2/202406:00GLOBEKymera Therapeutics to Report Fourth Quarter and Full Year..
09/2/202418:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:22EDGAR2Form 144 - Report of proposed sale of securities
31/1/202406:00GLOBEKymera Therapeutics to Present in Fireside Chat at the..
09/1/202408:17GLOBEKymera Therapeutics Outlines Key 2024 Objectives and..
09/1/202408:15GLOBEKymera Therapeutics Announces Closing of Upsized $275..
05/1/202415:11EDGAR2Form 8-K - Current report
05/1/202415:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/1/202405:00GLOBEKymera Therapeutics Announces Pricing of $275 Million Public..
04/1/202415:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/1/202415:01GLOBEKymera Therapeutics Announces Proposed Public Offering
04/1/202406:08EDGAR2Form 8-K - Current report
04/1/202406:00GLOBER&D Day Highlights Kymera’s Immunology Strategy and Emerging..
02/1/202416:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202406:00GLOBEKymera Therapeutics to Present at the 42nd Annual J.P...
13/12/202306:00GLOBEKymera Therapeutics to Host Virtual Immunology R&D Day on..
10/12/202320:00GLOBEKymera Therapeutics Presents Interim Results from STAT3..
07/12/202306:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
13/11/202310:00GLOBEKymera Therapeutics Announces Publication of Phase 1 Trial..
06/11/202317:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202308:15EDGAR2Form 8-K - Current report
02/11/202308:00GLOBEKymera Therapeutics to Present New Clinical Data from the..
02/11/202306:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202306:10EDGAR2Form 8-K - Current report
02/11/202306:00GLOBEKymera Therapeutics Announces Third Quarter 2023 Financial..
01/11/202306:00GLOBEKymera Therapeutics to Participate in Upcoming November..
27/10/202306:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
26/10/202306:00GLOBEKymera Therapeutics to Report Third Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock